secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0000879407-26-000037
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes
--------------------------------------------------------------------------------

- Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.
- Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.
- Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.
- KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.
- All other directors elected with over 90% support from votes cast (excluding broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/0000879407-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/arwr-20260319.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer